[Severe mixed thrombopenia during interferon treatment for chronic viral hepatitis C].
BACKGROUND
Thrombocytopenia occurred in a woman given alpha interferon for chronic hepatitis C without cirrhosis. Both central thrombocytopenia, clearly demonstrated, and peripheral thrombocytopenia, probably of autoimunne origin, were involved.


METHODS
A 55-year-old woman with active chronic hepatitis C (Metavir score A2, F2) was given alpha interferon. One month after treatment onset, she developed thrombocytopenia (32 G/L). A second bone marrow aspirate and osteomedullary biopsy evidenced megalokaryocytes and the platelet count responded to polyvalent immunoglobulins. Five months after discontinuing interferon, the platelet count progressively returned to normal.


CONCLUSIONS
Central thrombocytopenia is classically described in patients given interferon and usually appears during the first weeks of treatment. In our case, the central mechanism was clearly demonstrated by the bone marrow aspirate and osteomedullary biopsy findings at a time when the platelet count was 32 G/L. A peripheral immunological participation was more difficult to prove but was strongly suggested by the persistence of thrombocytopenia despite the interruption of the interferon and the efficacy of immunoglobulins.
Joseph-Reinette
C
C
Service d'Hépato-Gastroentérologie, CHU Trousseau, Tours.
Causse
X
X
Schoenwald
M
M
Lagasse
J P
JP
Doumerc
S
S
Labarière
D
D
Ardizonne
J F
JF
Legoux
J L
JL
D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
D007136:Immunoglobulins; D007372:Interferons